Sex-Related Characteristics and Short-Term Outcomes of Patients Undergoing Transcatheter Tricuspid Valve Intervention for Tricuspid Regurgitation.
Andrea ScottiAugustin CoisneMaurizio TaramassoJuan F GranadaSebastian LudwigJosep Rodes-CabauPhilipp LurzJörg HausleiterNeil FamSusheel K KodaliJoel RosieneAri FeinbergAlberto PozzoliHannes AlessandriniLuigi BiascoEric BrochetPaolo DentiRodrigo Estevez-LoureiroChristian FrerkerEdwin C HoVanessa MonivasGeorg NickenigFabien PrazRishi PuriHorst SievertGilbert H L TangMartin AndreasRalph Stephan von BardelebenKarl-Philipp RommelGuillem Muntané-CarolMara GavazzoniDaniel BraunBenedikt KoellDaniel KalbacherKim A ConnellyJean-Michel JuliardClaudia HarrGiovanni PedrazziniGiulio RussoFrançois PhilipponJoachim SchoferHolger ThieleMatthias UnterhuberDominique HimbertMarina Ureña AlcázarMirjam G WildStephan WindeckerUlrich JordeFrancesco MaisanoMartin B LeonRebecca T HahnAzeem LatibPublished in: European heart journal (2022)
After TTVI in high-risk patients, there were no sex-related differences in terms of survival, HF hospitalization, functional status, and TR reduction up to 1 year. The IPTW analysis shows a survival benefit of TTVI over medical therapy alone in both women and men.
Keyphrases
- aortic valve
- aortic stenosis
- ejection fraction
- mitral valve
- patients undergoing
- transcatheter aortic valve replacement
- end stage renal disease
- randomized controlled trial
- chronic kidney disease
- prognostic factors
- free survival
- polycystic ovary syndrome
- left ventricular
- pregnant women
- type diabetes
- stem cells
- coronary artery disease
- patient reported outcomes
- bone marrow
- atrial fibrillation
- adipose tissue
- insulin resistance
- cell therapy